This is a demo store. No orders will be fulfilled.

AKT Inhibitor VIII - ≥97%, high purity , CAS No.612847-09-3, Allosteric modulator of AKT serine/threonine kinase 1;Allosteric modulator of AKT serine/threonine kinase 2;Allosteric modulator of AKT serine/threonine kinase 3

In stock
Item Number
B304138
Grouped product items
SKU Size
Availability
Price Qty
B304138-5mg
5mg
3
$129.90
B304138-25mg
25mg
2
$585.90
B304138-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$848.90

Potent isozyme selective Akt1/2 kinase inhibitor

Basic Description

Synonyms 2-[[(5-methylimidazol-4-yl)methyl]thio]ethaneamine | GTPL5921 | SMR002157258 | UNII-YX4CPQ6V6X | Akt-I 1,2 | VU0450226-1 | 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one | AKOS016008792
Specifications & Purity Moligand™, ≥97%
Biochemical and Physiological Mechanisms Potent isozyme selective Akt1/2 kinase inhibitor. (IC 50 values are 58, 210 nM and 2.12 mM for Akt1, Akt2, and Akt3, respectively). No inhibition against pleckstrin homology (PH) domain-lacking Akts, PKA, PKC and SGK.
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Grade Moligand™
Action Type ALLOSTERIC MODULATOR
Mechanism of action Allosteric modulator of AKT serine/threonine kinase 1;Allosteric modulator of AKT serine/threonine kinase 2;Allosteric modulator of AKT serine/threonine kinase 3
Note Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

product description:

Akti-1/2 (Akt Inhibitor VIII) is a highly selective Akt1/Akt2 inhibitor with IC50 of 58 nM/210 nM, respectively, about 36-fold selectivity for Akt1 over Akt3. Akti-1/2 induces apoptosis.

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Organoheterocyclic compounds
Class Piperidines
Subclass Benzylpiperidines
Intermediate Tree Nodes Not available
Direct Parent N-benzylpiperidines
Alternative Parents Quinoxalines  Benzimidazoles  Phenylmethylamines  Benzylamines  Aralkylamines  Pyrazines  N-substituted imidazoles  Heteroaromatic compounds  Ureas  Trialkylamines  Azacyclic compounds  Organopnictogen compounds  Organooxygen compounds  Organic oxides  Hydrocarbon derivatives  
Molecular Framework Aromatic heteropolycyclic compounds
Substituents N-benzylpiperidine - Diazanaphthalene - Quinoxaline - Benzimidazole - Phenylmethylamine - Benzylamine - Aralkylamine - Benzenoid - Pyrazine - N-substituted imidazole - Monocyclic benzene moiety - Heteroaromatic compound - Imidazole - Azole - Urea - Tertiary aliphatic amine - Tertiary amine - Azacycle - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Amine - Aromatic heteropolycyclic compound
Description This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
External Descriptors Not available

Associated Targets(Human)

AKT3 Tchem RAC-gamma serine/threonine-protein kinase (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
AKT2 Tchem RAC-beta serine/threonine-protein kinase (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
AKT1 Tchem RAC-alpha serine/threonine-protein kinase (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Names and Identifiers

Pubchem Sid 504773221
Pubchem Sid Url https://pubchem.ncbi.nlm.nih.gov/substance/504773221
IUPAC Name 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
INCHI InChI=1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25,38H,14-17,20H2,(H,39,42)
InChIKey IWCQHVUQEFDRIW-UHFFFAOYSA-N
Smiles C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8
Isomeric SMILES C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8
Molecular Weight 551.66
Reaxy-Rn 38072815
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=38072815&ln=

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot Number Certificate Type Date Item
J2114042 Certificate of Analysis Aug 09, 2024 B304138
J2114043 Certificate of Analysis Aug 09, 2024 B304138

Chemical and Physical Properties

Sensitivity Light sensitive ;Heat sensitive
Molecular Weight 551.600 g/mol
XLogP3 4.300
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 5
Rotatable Bond Count 5
Exact Mass 551.243 Da
Monoisotopic Mass 551.243 Da
Topological Polar Surface Area 84.700 Ų
Heavy Atom Count 42
Formal Charge 0
Complexity 1270.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 1

Citations of This Product

1. Jie Liang, Dong-Kun Zhao, Hao-Ming Yin, Tai-Yu Tian, Jian-Kang Kang, Song Shen, Jun Wang.  (2025)  Combinatorial screening of nanomedicines in patient-derived cancer organoids facilitates efficient cancer therapy.  Nano Today,  61  (102665). 

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.